CA2976377A1 - Inhibition of yap for breaking tumor immune tolerance - Google Patents

Inhibition of yap for breaking tumor immune tolerance Download PDF

Info

Publication number
CA2976377A1
CA2976377A1 CA2976377A CA2976377A CA2976377A1 CA 2976377 A1 CA2976377 A1 CA 2976377A1 CA 2976377 A CA2976377 A CA 2976377A CA 2976377 A CA2976377 A CA 2976377A CA 2976377 A1 CA2976377 A1 CA 2976377A1
Authority
CA
Canada
Prior art keywords
yap
cells
cancer
cell
gvax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2976377A
Other languages
English (en)
French (fr)
Inventor
Fan Pan
Duojia Pan
Drew M. Pardoll
Joseph Barbi
Benjamin Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA2976377A1 publication Critical patent/CA2976377A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2976377A 2015-02-12 2016-02-12 Inhibition of yap for breaking tumor immune tolerance Pending CA2976377A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115414P 2015-02-12 2015-02-12
US62/115,414 2015-02-12
PCT/US2016/017697 WO2016130889A1 (en) 2015-02-12 2016-02-12 Inhibition of yap for breaking tumor immune tolerance

Publications (1)

Publication Number Publication Date
CA2976377A1 true CA2976377A1 (en) 2016-08-18

Family

ID=56615092

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2976377A Pending CA2976377A1 (en) 2015-02-12 2016-02-12 Inhibition of yap for breaking tumor immune tolerance

Country Status (7)

Country Link
US (1) US11491139B2 (https=)
EP (1) EP3256123B1 (https=)
JP (3) JP2018505223A (https=)
CN (1) CN107635582B (https=)
AU (2) AU2016219161A1 (https=)
CA (1) CA2976377A1 (https=)
WO (1) WO2016130889A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170085619A (ko) * 2016-01-14 2017-07-25 연세대학교 산학협력단 Alk 저해제에 대한 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 스타틴계 약물의 용도
US10925869B2 (en) 2016-05-26 2021-02-23 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating pulmonary vascular disease
WO2018085275A1 (en) * 2016-11-02 2018-05-11 The Regents Of The University Of California Targeting lats1/2 and the hippo intracellular signaling pathway for cancer immunotherapy
JP6886278B2 (ja) * 2016-12-01 2021-06-16 学校法人慶應義塾 抗癌剤
WO2018119418A1 (en) * 2016-12-24 2018-06-28 Nivien Therapeutics Company Methods relating to the treatment of chemoresistant and immuno-resistant cancer
WO2018132516A1 (en) * 2017-01-10 2018-07-19 Nodus Therapeutics Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US20200276125A1 (en) * 2017-11-22 2020-09-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition
US11360080B2 (en) * 2018-08-17 2022-06-14 National Health Research Institutes AhR-ROR-γt complex as a biomarker and therapeutic target for autoimmune disease and IL-17A-associated disease
SG11202107399WA (en) * 2019-01-31 2021-08-30 Ionis Pharmaceuticals Inc Modulators of yap1 expression
US20200323905A1 (en) * 2019-04-15 2020-10-15 Trustees Of Boston University Methods and compositions for modulating the immune system
US20210338265A1 (en) * 2020-04-30 2021-11-04 Ethicon, Inc. Methods and devices for delivering cancer therapy to a target tissue site via a cored tissue cavity
JP7514508B2 (ja) * 2020-05-19 2024-07-11 国立大学法人鳥取大学 胆道がん治療薬
KR20230093329A (ko) * 2020-10-28 2023-06-27 베이롤 칼리지 오브 메드신 암의 치료를 위한 면역조절 치료제로서 면역 세포에서 src-3의 표적화
CN113456633A (zh) * 2021-06-11 2021-10-01 广西医科大学 红海海绵素a在制备抗肺癌侵袭转移药物中的应用
CN118105483B (zh) * 2024-02-02 2025-03-11 济宁医学院附属医院 Ox40激活抗体和抗血管生成剂在制备抗肿瘤药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0605685D0 (en) * 2006-03-21 2006-05-03 Lytix Biopharma As Inhibition of tumour growth
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
US20040110731A1 (en) * 2002-12-04 2004-06-10 Chan Agnes H. Photodynamic therapy for the treatment of non-melanoma skin cancer
US20090304711A1 (en) * 2006-09-20 2009-12-10 Drew Pardoll Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
WO2011017809A1 (en) * 2009-08-11 2011-02-17 The University Of British Columbia Autophagy inhibitor compounds, compositions and methods for the use thereof in the treatment of cancer
EP2858635A1 (en) * 2012-06-11 2015-04-15 The Regents of The University of California Inhibitors of hippo-yap signaling pathway

Also Published As

Publication number Publication date
AU2021203851A1 (en) 2021-07-22
WO2016130889A1 (en) 2016-08-18
JP7186196B2 (ja) 2022-12-08
JP2022136162A (ja) 2022-09-15
CN107635582A (zh) 2018-01-26
CN107635582B (zh) 2022-08-02
EP3256123A1 (en) 2017-12-20
AU2016219161A1 (en) 2017-08-31
US20180021306A1 (en) 2018-01-25
US11491139B2 (en) 2022-11-08
JP2020164539A (ja) 2020-10-08
JP2018505223A (ja) 2018-02-22
JP7509830B2 (ja) 2024-07-02
AU2021203851B2 (en) 2023-08-31
EP3256123A4 (en) 2019-02-13
EP3256123B1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
AU2021203851B2 (en) Inhibition of YAP for breaking tumor immune tolerance
US12312398B2 (en) Compositions and methods for targeting activin signaling to treat cancer
JP6918279B2 (ja) 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物
DK2618835T3 (en) ANTIGEN-SPECIFIC T-CELL RECEPTORS AND T-CELL EPITOPES
US20240182543A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
WO2020146345A1 (en) Methods of treating cancer using lsd1 inhibitors and/or tgf-beta inhibitors in combination with immunotherapy
CA3023845A1 (en) Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer
JP2015529825A (ja) 癌幹細胞に発現する分子をターゲットとした癌を診断、治療する方法
KR20220092905A (ko) 입양 면역요법
US20230416746A1 (en) Immuno-oncology targets to improve t-cell metabolic response
CA3190792A1 (en) Methods and compositions for pancreatic cancer evaluation and treatment
EP4531891A2 (en) Activin signaling activity
US20250144107A1 (en) Use of a pikfyve inhibitor in combination with immunotherapy
Navarrete-Sirvent Nk cells as biomarkers of response to antiegfr therapy in metastatic colorectal cancer: clinical implications and therapeutic opportunities
EP3538549A1 (en) Or10h1 antigen binding proteins and uses thereof
Schlichtner Fundamental immunosuppressive pathway determining ability of cancer and embryonic cells to escape cytotoxic immune attack
CN120265755A (zh) 用于疾病治疗的t细胞-nk细胞相互作用抑制剂
CN117836327A (zh) 工程化的嵌合融合蛋白组合物及其使用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210212

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240909

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250207

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250207

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250207